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The evidence base supporting genetic and genomic sequence-variant interpretations is continuously evolving. An inherent consequence
is that a variant’s clinical significance might be reinterpreted over time as new evidence emerges regarding its pathogenicity or lack
thereof. This raises ethical, legal, and financial issues as to whether there is a responsibility to recontact research participants to provide
updates on reinterpretations of variants after the initial analysis. There has been discussion concerning the extent of this obligation in
the context of both research and clinical care. Although clinical recommendations have begun to emerge, guidance is lacking on the
responsibilities of researchers to inform participants of reinterpreted results. To respond, an American Society of Human Genetics
(ASHG) workgroup developed this position statement, which was approved by the ASHG Board in November 2018. The workgroup
included representatives from the National Society of Genetic Counselors, the Canadian College of Medical Genetics, and the Canadian
Association of Genetic Counsellors. The final statement includes twelve position statements that were endorsed or supported by the
following organizations: Genetic Alliance, European Society of Human Genetics, Canadian Association of Genetic Counsellors, Amer-
ican Association of Anthropological Genetics, Executive Committee of the American Association of Physical Anthropologists, Canadian
College of Medical Genetics, Human Genetics Society of Australasia, and National Society of Genetic Counselors.Introduction
The American Society of Human Genetics (ASHG) work-
group developed this position statement with evidence-
based justifications between January 2018 and November
2018. The workgroup is composed of a combination of lab-
oratory and clinical scientists, laboratory directors, medical
geneticists, primary care providers, bioethicists, health ser-
vices researchers, lawyers, and genetic counsellors. The
workgroup included representatives from the National So-
ciety of Genetic Counselors, the Canadian College of Med-
ical Genetics, and the Canadian Association of Genetic
Counsellors. The workgroup has reviewed the literature
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analysis aligns with a previously published return-of-re-
sults consensus statement1 and expands the discussion to
recontact research participants upon the return of updated
results from reanalysed genetic data.
The group met regularly through a series of bi-weekly
conference calls and email discussions and proposed a
draft outline of the statement to the ASHG Board of Direc-
tors in April 2018. A draft of this statement was reviewed
by the ASHG Board of Directors on October 15, 2018.
The Board requested revisions, which were reviewed by
the committee and incorporated in the current statement.
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October 19, 2018. There was a lively discussion, and addi-
tional comments were invited via email. The Executive
Committee of the Board reviewed and approved the cur-
rent, revised statement on November 15, 2018.
The final statement includes twelve position statements
that were endorsed or supported by the following organi-
zations: Genetic Alliance, European Society of Human
Genetics, Canadian Association of Genetic Counsellors,
American Association of Anthropological Genetics, Execu-
tive Committee of the American Association of Physical
Anthropologists, Canadian College of Medical Genetics,
Human Genetics Society of Australasia, and National Soci-
ety of Genetic Counselors.
Currently, research-related recontact typically happens
on an ad hoc basis, which can lead to inequitable informa-
tion provision and outcomes. Guidance is needed on how
recontact should be operationalized in both clinical and
research settings. This position statement addresses this
critical policy gap in order to provide necessary guidance
to our research communities. We recognize that not all
research studies return results; these recommendations
pertain to situations where the return of results has already
occurred with the approval of the institution’s IRB. These
recommendations are intended to provide a set of princi-
ples; ultimately, it is up to institutional review boards
and advisory boards as to how these principles are
operationalized.
Our statement acknowledges that the responsibility
to recontact a research participant could occur in some
instances when a researcher finds evidence to support the
reclassification of a variant according to professional stan-
dards.2 New knowledge might be learned about a variant
that was previously returned to a study participant, or a
medically relevant variant might be newly identified. In
either case, a strong responsibility is limited to situations
in which there are adequate resources to support such re-
contact (e.g., the research project is ongoing and has active
funding). ASHG acknowledges any participant’s right to
decline return of results at the time of recontact. Further
instances of recontact in this document imply that return
is offered, not that return is made without participant
agreement. Finally, the absence of an ASHG recommenda-
tion to recontact participants in situations other than
those enumerated below should not be interpreted as
ASHG opposition to recontact in other situations. Rather,
such omission indicates only that there is insufficient evi-
dence available at this time for ASHG to issue a recommen-
dation and that in such situations the determination
regarding recontact should bemade on a case-by-case basis.Scientific Background
The evidence base supporting genetic and genomic
sequence-variant interpretations is continuously evolving.
An inherent consequence is that a variant’s clinical signif-
icance might be reinterpreted over time as new evidenceThe Ameemerges regarding its pathogenicity or lack thereof. This
raises ethical, legal, and financial issues as to whether there
is a responsibility to recontact research participants to
provide updates on reinterpretations of variants after the
initial analysis. There has been discussion concerning the
extent of this obligation in the context of both research
and clinical care.3 Although clinical guidance has begun
to emerge,4,5 guidance is lacking on the responsibilities
of researchers to inform participants of reinterpreted
results.
What Does It Mean to Reinterpret Results?
Reinterpretation of genetic and genomic results might
occur at multiple levels. Most frequently, there is reinter-
pretation of the implications of one or more validated
sequence variants. This might occur as a revision of an
interpretation of the significance of a previously analyzed
variant, changing the status among the common cate-
gories of pathogenic (P), likely pathogenic (LP), variant of
uncertain significance (VUS), likely benign (LB), and
benign (B), effectively reclassifying the variant. Such rein-
terpretation might be the result of reanalysis within a
given laboratory after observation in another individual,
or it might be based upon new or revised data published
elsewhere about a particular variant or gene. Clinically,
P and LP are generally treated the same, and typically
VUSs are not acted upon (see CSER Toolkit in Web Re-
sources). Thus, changes between P and LP might not
have great consequence to participants, whereas changes
from P or LP to VUS, LB, or B or vice versa might.
New interpretations might emerge from sequence data
that had not previously been analyzed. This could be due
to the recognition of a gene or sequence of interest that
was not previously known to be relevant, changes in lists
of genes and sequences recommended for routine analysis
(e.g., the ACMG secondary findings list4), or revisions of
the scope and/or goals of a research project.
As a result of ongoing improvements in analytical
methods and bioinformatic analyses, resequencing of an
original specimen or reanalysis of raw sequence data might
lead to a newly detected variant that was missed as a result
of factors such as poor coverage or limitations in variant-
detection algorithms and filtration.6–16
The above situations might or might not justify an effort
on the part of the research team to recontact a participant
to disclose new information. In addition, recontact might
be considered appropriate if there is a change in a research
project’s threshold of what types of variants should be dis-
closed at all, such that variants that were uniformly not
disclosed in the past later meet criteria for disclosure after
a participant had originally received his or her results.
How Often Does Reinterpretation Occur?
There is a relatively high rate of reclassification
of variants, although the estimated rates vary across
clinical indications for testing. In two early publications,
Murray et al.17 found that over half of BRCA1/BRCA2rican Journal of Human Genetics 104, 578–595, April 4, 2019 579
VUS (60/107) were reclassified, the majority of these
(39/60) downgraded to benign. Aronson et al.18 reported
on 214 variant classification changes in 11 genes related
to hypertrophic cardiomyopathy over six years. More
than a quarter (56 variants) were upgraded from VUS to
LP, 26 were reclassified from LP to VUS, 32 were reclassified
from VUS to LB, another 25 variants changed between LB
and B, and 62 changed between LP and P. More recent re-
classification reports in both clinical and research settings
demonstrate that the majority of reclassifications are
downgrades,17,19–21 largely because of the emergence of
resources to document allele frequencies in diverse popula-
tions22 as well as more rigorous criteria for classifying path-
ogenic sequence variants.2 For example, Kast et al.19 found
18/40 VUSs downgraded to LB or B.
Importantly, a subset of cases of reclassifications can
impact clinical management through screening, treat-
ment, or familial testing recommendations.20,21,23 For
example, Turner et al. (2018)20 reported that 12% of reclas-
sifications (16/142) had the potential to alter clinical man-
agement: six of these were downgrades from P or LP to VUS
(in BRCA1, BRCA2, TP53, and CHEK2), and 10 were up-
grades from VUS to P or LP (in HNF1A, MSH6, BRCA1,
SDHD, and PMS2). Because surgery is often considered at
the time of diagnosis, in some cases individuals might
have undergone unnecessary surgeries by the time reclassi-
fication occurred. Indeed, Murray et al. (2011)17 report on
four women whose VUS was later reclassified to B but who
underwent risk-reducing mastectomy or oophorectomy. In
two cases, the documentedmain reason was ‘‘strong family
history of breast cancer.’’
These issues are further challenged by discordant (re)clas-
sification of variants and uncertainty of variant interpreta-
tions. Several studies have reported discrepancy rates in
variant interpretation between laboratories; such rates
have ranged from 39% to 66%.24–28 Bland et al. (2017)29
demonstrated that clinician experts’ classifications of vari-
ants differed from those of laboratories 18% of time, and
differences were generally clinically significant. They
found that clinicians tended to be more conservative in
their classifications. Shah et al. (2018)30 analyzed the
dynamics of reclassification of variant pathogenicity in
ClinVar over time; their analysis indicated progressive
improvement in variant classification and favored a general
direction away from P, LP, LB, and B. However, the bulk of
reclassified variants are reassigned to the ‘‘conflicting inter-
pretation’’ category. More recent analyses have shown a
more even distribution of upgrades and downgrades as lab-
oratories continue to resolve discrepancies in variant classi-
fication.31,32 Finally, reclassification rates also vary by
ancestry and ethnicity,33 highlighting potential disparities
in the rate of recontact among participant communities.
Stakeholder Perspectives
With the exception of a few studies,19,33–35 the evidence
base on stakeholder perspectives on recontact predomi-
nately originates from the clinical setting. Most of the liter-580 The American Journal of Human Genetics 104, 578–595, April 4,ature focuses on patient and professional preferences, but
evidence is emerging on the experience and feasibility of
recontact (albeit in the clinical setting). Thus, there is a
relative paucity of data on the most relevant population
for the purpose of this statement.
In the clinical setting, research addressing patients’ and
research participants’ perspectives on recontact indicates
that majorities of patients and participants surveyed
(69%–97%) across various disease groups felt that the phy-
sicians are responsible for recontacting patients about new
developments that could improve their or their family’s
care.35–38 One clinical study found that some patients
favor a ‘‘joint venture’’ of recontact, where patients and
healthcare providers share the responsibility for recon-
tact.39 However, patients appreciate the tension between
the desirability of recontact and a perceived lack of feasi-
bility.38 To this end, in at least some jurisdictions, patients
have recommended that health professionals ask patients
during their visits whether they want to be recontacted
and that they do so via personalized letters either annually
or ‘‘when new discoveries are made.’’35
Fewer studies have assessed professionals’ perspectives
on recontact. A 1999 survey of the ASHG membership
found that the community was divided on whether recon-
tacting clinical patients should be the ‘‘standard of care.’’40
Interestingly, scientists were more likely to perceive a re-
sponsibility to recontact than were clinicians (54% versus
43%).40 A Canadian survey of researchers found that
large majorities agreed that, in general and in a variety of
hypothetical research contexts, research teams that report
results should ensure that research participants gain subse-
quent access to updated information (74%–83%).41 Car-
rieri et al. surveyed clinical genetics service providers in
the UK and found that although the vast majority (95%)
reported that they recontact patients and their family
members, there are no standardized practices, and the
majority of services recontact on an occasional, not sys-
tematic, basis.42 Later the same authors interviewed 30
healthcare professionals and clinical laboratory scientists
and found that recontact was a concern; there were no
standard practices, and lines of responsibility in the clin-
ical context were unclear.38 These clinicians and clinical
scientists acknowledged that recontact requires multidisci-
plinary collaboration and that patients should sometimes
take on some of the responsibility. Participants also ex-
pressed a need for consensus about recontact and concerns
about the required infrastructure and resources.38
Recent evidence has begun to emerge about patients’
and research participants’ experiences with recontact. Taber
et al.34 surveyed ClinSeq research participants who had
been recontacted about new information pertaining to
their Duarte galactosemia variant, which had been reclassi-
fied from pathogenic to benign. They found that research
participants were able to understand variant reinterpreta-
tions of either a neutral change or a change from carrier
to non-carrier of a low-risk condition and that there were
minimal adverse effects (although all participants were of2019
high socioeconomic status). However, this change in clas-
sification would not have immediate impacts for these
research participants’ health; there is a need for more
research among research participants recontacted about
changes with greater personal health impacts. Romero37
surveyed clinical adult patients who had been recontacted
in light of new genetic tests related to their medullary thy-
roid carcinoma or pheochromocytoma or paraganglioma.
Only a minority of patients (29%, n ¼ 28) discussed
genetic testing with their doctor or genetic counselor
(9.5%), and 8.5% had genetic testing. Beunders et al.36 sur-
veyed parents of children who had received genetic testing
for Fragile X syndrome or intellectual disability; the par-
ents had been recontacted and offered new tests (array
CGH or whole-exome sequencing) that might be informa-
tive about their child’s diagnosis, and for themost part par-
ents reported positive experiences in the clinical setting
(83% were pleased to be recontacted, n ¼ 47).
Professionals’ experiences with recontacting offers
another perspective. The 1999 ASHG survey of the ASHG
membership indicated that although 61% of genetics pro-
fessionals have recontacted patients or research partici-
pants in the past, only 13% had a formal system in place
to do so.40 This was consistent in a recent survey of eight
Canadian diagnostic labs, where none had a protocol for
systematically reinterpreting previously analyzed vari-
ants.43 A European survey of 105 genetics centers demon-
strated that 95% (100/105) of clinical centers have recon-
tacted patients; of these, 37 centers did so routinely,
whereas 63 recontacted patients occasionally.44 Common
reasons justifying recontact efforts included availability
of a new test (n ¼ 55), new clinical guidance (n ¼ 33),
and reclassification of a VUS (n ¼ 26) to new results from
a prior test (n ¼ 17).44 Many European centers (41 of
105) have a formal system in place for recontacting pa-
tients; such systems include: clinicians seeking consent
at first visit, patients requesting or agreeing to future con-
tact, and clinicians recontacting patients without prior
consent (this was usually done when results were clinically
actionable [n ¼ 44] or were medically relevant to a relative
[n ¼ 16]).44 Interestingly, Beunders et al.36 compared the
feasibility and yield from recontacting their patients by
telephone versus letters. 36% of the 151 parents who
were informed by telephone made appointments for re-
evaluation, and 4% of the 52 parents who were informed
about recontact by letter did so. They also concluded that
recontact was very time consuming, especially in selecting
appropriate patients.
Overall, the evidence indicates that most stakeholders,
primarily representing the clinical setting, consider recon-
tacting patients or research participants to be ethically
desirable although practically difficult,45 and all point to
a need for greater guidance on this issue.
Current Guidance on Recontact
Currently, guidelines addressing recontact are sparse and
focus exclusively on the clinical context and not on theThe Ameresearch setting. Only two clinical guidelines explicitly
address recontact: a 1999 position statement from the
American College of Medical Genetics and Genomics
(ACMG) and a recently published guideline from the Euro-
pean Society of Human Genetics (ESHG5). The 1999
ACMG guidelines suggest that recontact might be merited
if new information is learned about a condition, but they
recommend that this be the responsibility of primary
care physicians who have more regular contact with pa-
tients than genetics specialists. The ACMG guidelines
also recommend that patients keep their primary care
physician informed or ask for updates about their results,
suggesting a dual responsibility for recontact. As of the
writing of this statement, the ACMG was in the process
of updating its guidelines. The ESHG recently recommen-
ded that clinicians recontact patients regarding findings
with clinical or established personal utility, yet there is
no legal or professional responsibility to do so.5 They add
that recontacting is a shared responsibility between pa-
tients and laboratories and that requests for reanalysis
should be initiated by the patient, clinical laboratory, or
the clinician.5
Additional policy statements from the Canadian College
of Medical Genetics (CCMG) and jointly from the ACMG
and American Association of Pediatrics (AAP) on other
topics have briefly addressed clinical recontact, but it has
not been the sole focus of any one recommendation.
ESHG and EuroGentest previously concluded that clinical
laboratories do not have a responsibility to routinely re-
analyze data but that if a variant is reclassified, the clinical
laboratory should identify patients affected by the change
and report this to their clinicians.46,47 The CCMG states
that re-analysis should be initiated by the clinician.48
The ACMG and AAP encourage recontact if a variant is re-
classified but leave it to the discretion of clinical labora-
tories to determine when to re-analyze data and when to
recontact patients.2 All statements point to a need for pol-
icies that specifically address when and how recontact
should occur in the clinical setting. There is a paucity of
guidance about recontacting participants in the research
setting.
Scope of Statement
Recontacting research participants after reinterpretation of
genetic and genomic research results is a complex issue in
which clinical and research laboratories, clinicians and re-
searchers across specialties, and research participants all
have potential roles to play. Currently, research-related re-
contact typically happens on an ad hoc basis, and this
might cause inequitable information provision and out-
comes. There is a need for guidance on how recontact
should be operationalized and when and how it should
occur, especially in the research setting—a setting where
no guidance currently exists.
This position statement addresses this critical policy gap
in order to provide necessary guidance to our research
communities. It limits its recommendations to primarilyrican Journal of Human Genetics 104, 578–595, April 4, 2019 581
research settings while recognizing that genetic and
genomic research results often impact clinical and other
contexts. Indeed, even within a given research study or
registry, there are varying degrees of crossover into the clin-
ical realm (e.g., the MyCode Community Health Initiative
at Geisinger). This statement attempts to address these
research and clinical ‘‘grey zones’’ but recognizes that addi-
tional input from other stakeholders will be important as
experience with, and the evidence base of, recontacting
research participants grows.
Exclusively clinical contexts are outside the scope of this
position statement, given the existing guidance on the
topic. The position statement also avoids discussions
related to researchers’ obligations to recontact family or
representatives of decendents when the proband or
research participant is deceased because this is the focus
of separate guidance recommending that researchers
have no obligation to return results to relatives (when
the proband is deceased) and no ‘‘duty to hunt’’ for such
results.49 Cases where initial consent was received while
a participant was a minor and any related discussion as
to what happens when such individuals reach adulthood
are also beyond the scope and intent of this statement.
This document focuses exclusively on the recontact of
study participants after the initial return of research re-
sults and does not address the issues relevant to initial re-
turn of a result. In other words, should reinterpretation
occur in the context of interpretation of a gene not previ-
ously analyzed, then study protocols should be followed.
This document instead focuses on the recontact of partic-
ipants when a variant has already been returned and,
subsequently, when a reinterpretation of that variant
is made. The ASHG endorses a prior consensus statement
on the initial return of genomic results to research
participants.1
Ethical Principles
It is important to ground this guidance in an appropriate
set of ethical principles because policies addressing these
issues should strive to reflect the same principles applied
across all types of research ethics questions. It is appro-
priate, then, to start with the principles proposed in the
Belmont Report, the document that provided the ethical
foundation for modern research regulations in the United
States.50 The Belmont Report suggests that three principles
provide the foundation for ethically appropriate research
with human participants: respect for persons, beneficence,
and justice. Commonly cited overlapping principles
grounded in medical ethics come from Beauchamp and
Childress: beneficence; non-maleficence; respect for per-
sons and autonomy; and justice.51
Among these three principles, respect for persons is
potentially the most expansive. The framers of the Bel-
mont Report interpreted this principle primarily from the
perspective of autonomy: researchers are obligated to
demonstrate respect for research participants by ensuring
that participants have the opportunity to consider the risks582 The American Journal of Human Genetics 104, 578–595, April 4,and benefits of the research and voluntarily agree (via an
informed consent process) to participate in the research.
By emphasizing autonomy, this principle emphasizes
that a broad range of approaches to returning genetic
and genomic results revealed through reanalysis can
potentially be ethically acceptable if one assumes that
this approach is made clear during the consent process to
which the research participant has knowingly agreed.
This is also, of course, why it is more difficult to deal
with these issues when a plan has not been developed pro-
spectively and included in the consent process.
It is also important to recognize that the obligation for
researchers to demonstrate respect for the participants
could entail a number of other important ethical princi-
ples.52,53 Chief among these is the ethical principle of ve-
racity, or truth telling. In general terms, this aspect of the
principle of respect for persons holds that researchers
should not lie to participants unless there is scientific
reason to do so (such as in psychological research that in-
volves misdirection).54 The ethical principle of veracity
supports a limited obligation to return reinterpreted results
because the communication of the original research results
to a participant could be seen as information that is now
known not to be true, such that there is a limited obliga-
tion to correct the false information. As always, this inter-
pretation of veracity would need to be weighed along with
a range of other ethical principles.
In the research context, the principle of beneficence
functions slightly differently from the way it is applied to
clinical care.55 In the clinical context, beneficence holds
that healthcare providers have a fiduciary duty to pursue
the best interests of their patients. In the research context,
maximizing benefits and minimizing risks to research par-
ticipants needs to be weighed against the overall aim of
research: to generate new, and important, scientific knowl-
edge. It is necessary for researchers to carefully consider
how to pursue scientific knowledge by using an approach
that confers the best possible balance of risks and benefits
to participants while still generating the benefits of high-
quality research. In other words, any responsibility that re-
searchers have to provide benefits to their research partic-
ipants (also known as an ancillary-care responsibility) is
necessarily a limited responsibility.56
Justice, when applied to human research, can be opera-
tionalized in three ways in the context of the scientific
value of research. First, researchers should be just in recruit-
ing and enrolling participants in research studies. Except
where justified by the scientific goal of the research, partic-
ipants should have both equal access to the benefits of the
research and equal exposure to its risks.57 Second, deci-
sions about the funding of research also need to be guided
by the principle of justice. Third, because the risks associ-
ated with human research are justified largely by the po-
tential benefit of research to generate scientific knowledge
and provide benefit to society at large, both researchers
and funders might need to prioritize scientific aims over
other aims. For example, imagine that a psychological2019
study is being conducted in a primary-care clinic to answer
an important scientific question, but the study also pro-
vides a mechanism for patients to receive psychological
treatment. If that psychological treatment ends up being
more expensive than originally anticipated (i.e., because
participants need more intensive therapy than expected),
then researchers might need to curtail this ancillary care
in order to ensure that enough budget is available for the
study to achieve its scientific aims. The principle of justice
dictates that the scientific aims of a research study must be
protected, or else the risks assumed by participants would
not have been justified.
These related aspects of beneficence and justice high-
light the importance of practicability in applying ethical
principles to the conduct of scientific research. There are
a wide range of practices that researchers might want to
adopt but that would not be absolutely necessary for a
research study to achieve its goals. For example, clinical
study personnel sometimes send birthday cards or newslet-
ters as a way to maintain participants’ engagement with a
research study. Biorepositories sometimes choose to return
individual research results to participants to help prevent
participants from experiencing adverse health events. If
it is possible to successfully carry out these practices, and
to do so without threatening the overall ability of the study
to achieve its scientific aims, then these practices can be
said to be practicable—they are capable of being done
while not threatening the goals specific to a research study,
i.e., to generate scientific knowledge and provide societal
benefits.1
Practicability, then, provides a way to ethically weigh the
potential conflicts that might arise in trying to balance
ethical principles. The efforts of biorepositories to return
individual research results to participants can be seen as
a way to express respect for the contributions that partici-
pants havemade to research.52 Although this expression of
respect can be seen as an ethical good, this good must be
weighed against other ethical goods. As we have seen,
the principle of justice could limit this particular expres-
sion of respect for persons if, in fact, an effort to return in-
dividual research results would prevent the biorepository
from achieving its scientific aims (i.e., because it costs
too much or because it requires too much effort from
research staff).
As one thinks about potential reasons that a researcher
might need to return reinterpreted findings to partici-
pants, practicability provides a valuable framework for
considering when this might or might not amount to
an ethical obligation. Assuming that researchers utilize
criteria that ensure the potential benefits of returning up-
dated findings are maximized, taking on this additional
effort would clearly provide an ethical good. However,
whether there would be an ethical obligation to provide
this good depends on a number of contextual factors.
Practicability requires that the primary obligation of the
researcher is to ensure that the research being conducted
is completed successfully and is used to provide the scien-The Ametific knowledge and societal benefit that it was designed to
provide and thereby justify the risks that participants
have assumed. Where this aim can be achieved while at
the same time providing the service of reanalysis and re-
turn of updated results, making this effort clearly could
provide additional benefit to research participants. How-
ever, where there are no resources at all to carry out this
extra effort (e.g., after the funding for a research study
has ended) or where it cannot be carried out without
interfering with the study’s scientific aims (e.g., when it
would consume grant funds that are required to complete
the study), then a case could be made that it would be un-
ethical or impossible to pursue the return of reinterpreted
results.
The use of practicability as a standard for deciding
when there might be a responsibility to return reinter-
preted results creates an obvious challenge: How should
decisions be made about what is practicable? An impor-
tant concern, of course, is that if the decision is left to re-
searchers alone the researcher might determine that an
effort to return reinterpreted results is not practicable,
when in fact it is practicable but inconvenient. From a
pragmatic perspective, then, it is important that such
decisions not be left solely to researchers. Typically,
IRBs make these types of evaluations after allowing re-
searchers to present justification, and the IRB then makes
a final decision. However, other models of research
governance are possible, and IRBs might approve plans
to use advisory boards (such as groups of internal stake-
holders or community advisory boards) to make these
types of decisions.
With all of this in mind, however, it is worth re-empha-
sizing that a broad range of approaches to returning up-
dated results can be permissible. Assuming these plans
are developed prospectively, an IRB needs to evaluate
them to ensure that the principles of respect for persons,
beneficence, and justice are being respected to the extent
possible, and then a thorough informed consent process
must be included so that participants have enough infor-
mation to voluntarily agree to the plan.
In summary, then, on the basis of these ethical princi-
ples, the obligation to recontact research participants is
stronger when
d The research is active, ongoing, and has funding and
the participant’s contact information is up to date
(practicability);
d Informed consent set the expectation for potential re-
contact (respect for persons and autonomy);
d There is a high degree of certainty about the new
interpretation and/or implications of a changed inter-
pretation, as judged by both investigator and IRB or
governance structure (non-maleficence); and
d The reinterpretation would be relevant to the condi-
tion under study or, in the case of an actionable inci-
dental finding, likely to change medical management
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Legal Implications45,49,58–75
It is also important to ground this guidance in an appro-
priate set of legal principles, the first of which is consider-
ation of fiduciary relationships. Fiduciary relationships are
ones in which a person in a position of greater power is un-
der an obligation to act for the benefit of another within
the scope of the relationship. In other words, the fiduciary
is to have undivided loyalties to the beneficiary. Fiduciary
relationships might rise from contractual agreement, and
it is important to recognize that fiduciary duties do not
arise simply by virtue of an imbalance of expertise. A fidu-
ciary duty is based in trust and is highly contextual. Absent
explicit legislative authority establishing affirmative duties
on researchers, courts in the United States have generally
been unwilling to find that a researcher has fiduciary duties
to research participants unless the researcher is also the
participants’ treating physician. Although the physician-
patient relationship has been described as a fiduciary
one, this characterization has been framed distinctly
from general tort duties related to fulfilling the standard
of care. One rationale for maintaining a false dichotomy
between care and research is based on the notion of con-
flicts of interest. A treating physician’s primary duty of loy-
alty is to the individual patient to ensure the improvement
or maintenance of the health and wellbeing of that indi-
vidual patient; however, a researcher’s primary duty of loy-
alty is to scientific enterprise itself and the production of
generalizable knowledge rather than the provision of any
direct benefit to an individual participant. Another basis
for the dichotomy has been the now fading conceptualiza-
tion of participation in research as a transactional activity
(requiring informed discussion and consent only at the
time of initial enrolment in the research) rather than a
participatory one (with ongoing communication and
interaction as appropriate). Courts have been unwilling
to extend fiduciary duties to researchers and have noted
the countless questions such an extension would raise
(e.g., how long such a fiduciary duty would last, whether
the duties would persist beyond the participation in the
research, and how to determine the scope of institutional
duties that would arise vicariously).
Researchers could have duties arising from other the-
ories, including general negligence (that is, failing to
perform responsibilities according to the prevailing
professional standard). As norms for the profession shift
to accommodate more equitable and participatory ap-
proaches to research, genetics researchers could be
required to stay current with technologies and methods
as well as to provide participants with updated disclosures
related to information previously disclosed or later ac-
quired information. The prevailing professional standard
for the conduct of genetics research is set, in part, by the
issuance of position statements and recommendations by
professional organizations, such as the ASHG. The recom-
mendations provided in the present statement are not in-
tended to establish a legal duty, although courts might
find these recommendations useful if called upon to estab-584 The American Journal of Human Genetics 104, 578–595, April 4,lish, define, or otherwise delineate the scope of a responsi-
bility to recontact research participants.
In addition to agencies and oversight authorities that
might establish and occasionally revise codes of conduct
and set performance obligations that researchers owe to
their participants, research institutions and research
sponsors might also have their own policies that relate
to a responsibility to recontact participants. The recom-
mendations provided in the present statement are not in-
tended to supersede other policies. Researchers should
consult their attorney and relevant administrators to
reconcile any discrepancies between these recommenda-
tions and any and all applicable laws and policies for
the situation.
Recommendations
What—Nature of Results
The responsibility to recontact a research participant could
occur in some instances when a researcher finds evidence
to support the reclassification of a variant according to
professional standards.2 New knowledge might be learned
about a variant that was previously returned to a study
participant, or a medically relevant variant might be newly
identified. In either case, a strong responsibility is limited
to situations in which there are adequate resources to sup-
port such recontact (e.g., the research project is ongoing
and has active funding). The ASHG acknowledges any
participant’s right to decline the return of results at the
time of recontact. Further instances of recontact in this
document imply that return is offered, not that return is
made without participant agreement. Finally, the absence
of an ASHG recommendation to recontact participants
in situations other than those enumerated below should
not be interpreted as the ASHG’s opposition to recontact-
ing them in other situations. Rather, such omission indi-
cates only that there is insufficient evidence available at
this time for the ASHG to issue a recommendation. In
such situations, the determination regarding recontact
should be made on a case-by-case basis.
Given these considerations, the ASHG offers the
following recommendations:
1. The ASHG strongly recommends attempting to recon-
tact participants to offer updated results if the rein-
terpretation is related to the phenotype under study
or is reasonably expected to affect a research partici-
pant’s medical management.
2. If the reinterpretation is not expected to affect man-
agement, recontact is advised, rather than strongly
recommended, for correction of the classification of
a variant previously reported to the participant and
whose pathogenicity classification has changed
from or to pathogenic or likely pathogenic.
The strength of ASHG’s recommendations to recontact
diminishes when the evidence for medical benefit is less2019
definitive. Clinical criteria for ‘‘affecting medical manage-
ment’’ are defined elsewhere by the ACMG and could serve
as a resource for researchers; they include4,76
d serious conditions
d highly penetrant variant
d effective intervention available (screening or treat-
ment)
d risk/benefit profile of intervention is favorable
d strong knowledge base about condition overall
All of the above applies to disclosure of both primary and
additional,77 also called secondary or incidental, findings.
For primary findings related to the participant’s phenotype
under study, if changes are of clinical consequence (from
P or LP to B, LB, or VUS or from B, LB, or VUS to P or
LP), then recontact is advised, even in the case where med-
ical management of the individual being tested will not
clearly change, for example in most patients with already
diagnosed cardiomyopathy.
It is acknowledged that expectations and decisions about
medical management are appropriately shared between
health care providers and patients and that there are situa-
tions in which expectations between patients and health
care providers are not aligned. For the purposes of recom-
mendation #1, the determination of what is ‘‘reasonably
expected to affect medical management’’ is to be consid-
ered from the perspective of the researcher but should be
informed by clinical guidelines and, when practical,
consultation with clinicians.
What—Threshold Considerations
In general, thresholds should be considered relative to
what a research participant has been led to believe on
the basis of results that either have or have not been dis-
closed to them already18 and what was stated in the
research consent if recontact was addressed.
The rationale for recontacting participants is strongest
when
d a participant has been notified of a LP or P variant,
which is later downgraded to VUS, LB, or B;
d researchers have told a study participant that no
detectable variants of clinical significance have been
identified, and a LP or P variant that might impact
medical management is subsequently identified or re-
classified from VUS, LB, or B; or
d researchers have implied that a study participant har-
bors no detectable variants of clinical significance
because no results have been returned, and a LP or
P variant that might impact medical management is
subsequently identified.
Recontact is advised when VUSs were returned and are
reclassified as LP or P. However, recontact in these situa-
tions falls short of a strong responsibility for the following
reasons.The Amed By definition, VUSs are subject to revision on the ba-
sis of changing evidence. Research participants who
have VUS returned to them as part of research are
(ideally) encouraged to seek clinical follow-up testing
and counselling in the future.
d There is even less responsibility if reclassification of a
VUS to LP or P is not believed to impact medical man-
agement.
d Recontact for reinterpretations from B or LB to VUS
should be made on a case-by-case basis when there
is anticipated benefit.
Researchers have no responsibility to hunt through or
scan genetic and genomic data or literature for changes
in variant interpretation or to identify new genetic causes
of disease, if such was not part of the original study.1,78,79
To do so would be outside the scope of what a researcher
owes a study participant and might detract from the pri-
mary goals of research. This position is consistent with
consensus that exists among clinical diagnostic labora-
tories, which also do not have a duty to hunt for variant re-
classifications,46 and with our endorsement of a prior
consensus statement on the return of genomic research
results.1 However, evidence supporting variant reclassifica-
tion might arise as part of a researcher’s work (e.g., via
functional studies, literature searching, or data sharing).
Researchers are responsible for the validity of variant clas-
sification and are urged to critically evaluate the source of
and evidence supporting each classification.
Given these considerations, the ASHG offers the
following recommendation:
3. The ASHG recommends that there is no responsibil-
ity for researchers to hunt or scan genetic and
genomic data or literature for changes in variant
interpretation.
When—Temporal Considerations
Consistent with related guidelines,1 no return of results
should be expected after the close of study funding.
4. The ASHG recommends that any responsibility to
recontact research participants is limited to the dura-
tion of research funding. Recontact after the conclu-
sion of funding may be desirable if sufficient re-
sources exist.
It is important to distinguish temporal issues that one
must consider prospectively when planning a study from
those for ongoing studies, where the question of recontact
emerges after study initiation.
For prospective studies, researchers should plan to com-
plete any recontact for interpretations of variants related to
the phenotype under study and/or reasonably expected to
affect a research participant’s medical management.
For ongoing studies in which there is no existing plan for
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any recontact related to reinterpretations of variants
related to the phenotype under study and/or reasonably
expected to affect a research participant’s medical manage-
ment (as defined in sections ‘‘What—Nature of Results’’
and ‘‘What—Threshold Considerations’’) is indicated prior
to the end of study funding. The need for clinical confir-
mation of a research result might influence the process of
recontact but is not expected to influence the timing.
Funding for recontact might be challenging when not
planned in the budget of an ongoing study. However, as re-
viewed in section ‘‘How Often Does Reinterpretation
Occur?’’, the proportion of cases with variants whose re-
classification has both strong scientific evidence and impli-
cations formedical management is likely to bemodest.20,21
In some cases, especially large-scale sequencing studies
that choose to recontact participants with regard to vari-
ants beyond those related to the phenotype under study
and/or those reasonably expected to affect a research par-
ticipant’s medical management, supplemental funding
might be necessary.
5. The ASHG recommends that no responsibility to re-
contact participants exists when the IRB protocol
associated with the study closes or identifiers are
stripped, rendering further recontact infeasible.
When the study protocol to which the participant con-
sented closes, and IRB oversight ceases, the researchers’ re-
sponsibility for recontact ends. Should the study’s prin-
cipal investigator change in an ongoing study (such as a
longitudinal study), ultimate responsibility for recontact
is transferred in the same way as for responsibility of other
study functions.
6. The ASHG recommends that, when there is a strong
recommendation for recontact, the recontact should
occur within 6 months of the reinterpretation.
When the certainty of the reinterpretation, the gene-dis-
ease association, and/or the medical relevance is less defin-
itive, a longer duration for recontact is reasonable or even
desirable, so as to allow more time to establish more cer-
tainty. A longer duration is also reasonable when recontact
is pursued for reasons related to personal utility rather than
medical management (where personal utility refers to non-
clinical benefits endorsed by patients; such benefits might
include [but are not limited to] family or reproductive
planning, life preparation, empowerment, and advanced
knowledge80). Such delay should be balanced against the
risk that study funding or other resources might not be suf-
ficient to support recontact in the future.
As previously established, there is no ‘‘duty to hunt’’ or
duty to re-analyze unless otherwise specified in the
research consent or protocol. Likewise, there is no prede-
termined timeframe for a frequency of reanalysis. The
timeframes relate to the time since discovery of new evi-
dence during the course of research. An example would586 The American Journal of Human Genetics 104, 578–595, April 4,be if a researcher reclassified disease-specific variants per
the 2015 ACMG/AMP criteria2 prior to publication and
in the course of this process, realized that some variants
previously adjudicated and returned as LP or P are now
classified as VUS, LB, or B.
How—Operational Issues
The ASHG offers the following recommendations concern-
ing operationalizing recontact:
7. The ASHG recommends that instances of recontact
be documented.
8. The ASHG recommends that any responsibility for
recontact is limited to a ‘‘good faith effort’’ to reach
the participant within the limits of existing con-
straints, including (but not limited to) financial
and personnel resources, the existence of accurate
contact information for the participant, and willing-
ness of the participant to accept recontact.
For variant reinterpretation that is related to the pheno-
type under study and/or reasonably expected to affect a
research participant’s medical management and a high cer-
tainty of evidence supporting reclassification (as defined
in section ‘‘What—Nature of Results’’ and ‘‘What—
Threshold Considerations’’), it is reasonable for researchers
to make this information available to participants through
direct individual contact if consistent with the overall
study return-of-results policy. For reinterpretations of vari-
ants unrelated to the phenotype under study and/or not
expected to affect a research participant’s medical manage-
ment where individual results had already been returned,
a broad-based notification (such as a newsletter or generic
mailing) to study participants will most likely suffice.
It is important to distinguish operational issues that
need to be considered prospectively during the planning
of a study versus those for ongoing studies, where the ques-
tion of recontact emerges after study initiation.
For prospective studies, as part of an overall return-of-re-
sults plan, researchers should anticipate the possibility of
needing to recontact participants after reclassification of
variants and design the study protocol accordingly. This
includes developing a process for maintaining communi-
cationwith participants as well as ensuring necessary fund-
ing and staffing. Considerations for recontact for updating
genetic and genomic results are similar to those regarding
operational issues of best practices for return of initial ge-
netic and genomic study results.4
For ongoing studies that did not consider recontact in an
initial return-of-results plan, but where variant reclassifica-
tion has prompted consideration of recontact, initial pol-
icies for release or disclosure of original genetic findings
should be followed to the extent possible and should
obtain IRB or ethics approval as needed. This includes,
for example, decisions related to return of only clinically
validated results versus research results, the actual form
of recontact (e.g., mail, electronic, or web-based), security2019
considerations, notification of relatives of deceased partic-
ipants, and documentation. For instance, in some circum-
stances documentation of reclassification within a report
addendum in the medical record is warranted if the initial
return-of-results protocol included deposition of genetic
results into themedical record but not if initial return of re-
sults was limited to a personalized results letter to the study
participant.
How—Issues of Consent
Informed consent and recontact first requires taking note
of the informed consent and basic return of individual
research results. It is important to distinguish consent is-
sues that need to be considered prospectively during study
planning versus those for ongoing studies, where the ques-
tion of recontact emerges after study initiation.
For prospective studies:
9. The ASHG recommends that research projects
develop a plan not only for initial return of results
but also for return (or not) of reinterpretations of
those results. As part of that plan, research partici-
pants should be alerted to the likelihood that inter-
pretations of results might change over time and be
given the opportunity to provide informed consent
regarding the plan for return of results, including
initial and reinterpreted results.
This position is consistent with numerous recommenda-
tions that have stated that researchers should anticipate
the possibility of returning individual genetic research re-
sults.1,64,79,81,82 Fabsitz et al.81 state: ‘‘Researchers should
consider prospectively whether their study has potential
to yield individual research results of clinical importance
and describe plans for return of results in consent forms
and processes.’’ As such, researchers should either state in
the consent document that the participant might be con-
tacted in the future and offered a research result or ask
the participant in the consent document whether or not
he or she would want to be contacted in the future to learn
about a research result. Jarvik et al.1 further expound on
this by saying ‘‘The consent process and form should
address the possibility that theremight be both research re-
sults related to the primary intent of the research and find-
ings that are incidentally discovered in the course of
research, and participants should be able to clearly opt in
or out of receiving these types of results either at the
time of initial consent or at a later point in the study
when the specific types of results the participants might
receive can be best defined. [.] Ideally, the original con-
sent form would include the possibility for, or an option
of, future contact to offer results not anticipated at the
time of consenting.’’
Limitations include the fact that technologies, and
therefore responsibilities, are rapidly changing, and
many studies have consent forms developed (and signed)
when the breadth of findings and possibility for reinterpre-The Ametations was poorly anticipated. Researchers should develop
a plan for recontacting research participants in the future
and include it in the consent form, and they should
include an option to decline future recontact entirely.1,83
For ongoing studies, the original research consent docu-
ments are relevant in defining what will or will not be
analyzed, re-analyzed, and disclosed to research partici-
pants in the present and in the future. Original research
consent documents are also relevant in determining
how to approach whether or not to recontact partici-
pants.1,64,79,81,82 A consent document that explicitly ad-
dresses the issue (by either stating or requesting permis-
sion) is a different situation than a consent document
that ignores the issue (i.e., by not stating either way
whether recontact might or might not occur).
If the research consent documents address the issue of
recontact, the situation is fairly clear cut, and recontact
can be initiated. If participants agreed to have individual
results returned, it implies that the participant has also
agreed to being recontacted about the same type of results.
10. The ASHG recommends that, if the participant con-
sented to any return of results at the time of original
research consent, then consent to recontact for the
same type of results is implied and therefore appro-
priate subject to the other recommendations in this
policy statement.
If the research consent documents do not address the
issue of recontact or of return of research results, then de-
pending on the nature of the information, researchers
can and should turn to a research ethics consultation
service (e.g., the Clinical Research Ethics Consultation
Collaborative [RECs]) and/or an IRB for guidance.81,84–86
In addition, a formal determination will most likely need
to be made through a conversation between the researcher
and the local IRB. This discussion must take into account
the specific details of each case in question.
Of note, some institutions might have a local policy
requiring the return of any research finding (regardless of
whether it is the initial return or a recontact to return re-
classified results) to be approved by the IRB, even if it
was stated in the protocol that these might happen. That
is, the local IRB might want to see the list of variants being
returned (initially or as part of a recontact to return reclas-
sified results) and justification for their return.
Participants might change their minds regarding return
of results over time. In situations where researchers feel a
strong desire to overrule participants’ initial consent to re-
turn initial results in order to recontact participants with
reinterpreted variants, researchers should seek REC’s
guidance.
Who—Professional Roles
Ideally, recontact protocols, along with consideration for
protocols that take into account the context and limita-
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research study design in consultation with the IRB
approving the study. In cases where no protocol or proced-
ure for recontact was previously put in place and recontact
is warranted according to the specifications outlined earlier
in this document, the points below should be considered.
When in doubt, researchers should consult with the IRB
under which the research study was approved.
The ASHG offers the following recommendation to
operationalize the recontact of research participants:
11. The ASHG recommends that, ideally, the same indi-
viduals and communication methods that were
used for the initial return of results should be used
for recontact.
Because recontact implies that an initial contact took
place, ideally the same channels should be used for recon-
tact and initial contact for the same type of result. For
example, a research protocol can suggest that negative
and uncertain results are returned by letter, whereas detec-
tion of the P or LP variants or medically actionable inci-
dental findings are returned by telephone or personal
meeting. Ideally, the same individuals involved in the prior
contact should be involved with recontact. If the individ-
uals initially involved left the institution, then ideally
the individual(s) who assumed their professional role will
carry out the recontact. In cases where no designated indi-
vidual assumed this professional role, another member
of the same team with similar credentials would be the
preferred individual to carry on the recontact. If none of
these options is available, the research team should notify
research participants according to the mechanisms out-
lined earlier in this document. If a clinician was initially
involved in referring a patient-participant to the study
and/or managing study results, the research team should
alert him or her to the new results.
It is recognized that participant clinical access might be
limited by funding considerations and/or limited special-
ized human resources. As such, although the information
might be made available to clinicians, clinicians should
act according to the clinical guidelines and protocols that
apply in the jurisdiction.
There is a paucity of literature on duality of roles (clini-
cian researchers) with the exception that perceived or
real conflicts of interest should always be considered in
the context of recontact, and a result conveyed by a health-
care provider who is actively treating the patient-partici-
pant is less likely to be perceived as value neutral by the
participant, even if that provider is acting as a researcher
at the time of conveying that result. A therapeutic inten-
tion is often assumed in such situations, even when pa-
tients are told otherwise.1,87,88
As noted above, the absence of an ASHG recommenda-
tion to recontact participants in situations other than
those enumerated above should not be interpreted as
ASHG opposition to recontacting participants in other sit-
uations. Rather, such omission indicates only that there is588 The American Journal of Human Genetics 104, 578–595, April 4,insufficient evidence available at this time for the ASHG to
issue a recommendation. In such situations, the determi-
nation regarding recontact should be made on a case-by-
case basis. However, as noted elsewhere1, ‘‘researchers
might be ethically and scientifically justified in returning
all genomic information.’’ If they are returning broader
classes of information, theymight be justified in recontact-
ing participants about broader types of reinterpreted
results.
12. The ASHG acknowledges that in the research
context, participants might consent to initial re-
turn of a much wider range of results. Thus, it is
appropriate to return reinterpretations derived
from reanalysis broader than those addressed in
this statement when that is consistent with study
design and consent documents.
See Box 1 for a full list of recommendations and Figure 1
for a recommended pathway for considering recontact.Discussion
It is now well recognized that researchers should antici-
pate situations in which the return of study findings
might become appropriate.1,4,49,89 With recent data docu-
menting the relatively high rate of reclassification of var-
iants, researchers planning a study should likewise antici-
pate and plan for recontacting study participants during
the life of their funded studies. Herein, the ASHG sets
the minimum principles underpinning researchers’ re-
sponsibilities to recontact their research participants
about variant reclassifications.
A common theme in most critical evaluations of recon-
tact is the inherent tension between the desire to keep
research participants as informed as possible and the op-
portunity costs and practical challenges of actually accom-
plishing that goal. Depending upon the details of a given
situation, the degree of ethical imperative for recontact
and the associated obstacles might vary. There are different
types of utility as well as potential harm, some of which are
clearly medically actionable and have quantitatively
measurable effects on morbidity and mortality, whereas
others are more personal, intangible, and qualitative. The
resource costs of recontact depend on multiple factors,
including accessibility of the intended recipient of the re-
contact, the experience of the clinician or researcher, and
the nature of the revised interpretation. Funding for those
resource costs might be uncertain, especially after a study
has closed, and any budget devoted to recontact neces-
sarily represents resources that were not dedicated to
some other purpose.
These recommendations have been developed amidst an
evolving landscape of related policies and guidance docu-
ments. For example, the recent report (titled ‘‘Returning
Individual Research Results to Participants: Guidance for2019
Box 1. Recommendations for Recontacting Participants after Reinterpretation of Genetic and Genomic Research Results
1. The ASHG strongly recommends attempting to recontact participants to offer updated results if the reinterpre-
tation is related to the phenotype under study or is reasonably expected to affect a research participant’s med-
ical management.
2. If the reinterpretation is not expected to affect management, recontact is advised, rather than strongly recom-
mended, for correction of the classification of a variant previously reported to the participant and whose path-
ogenicity classification has changed from or to pathogenic or likely pathogenic.
3. The ASHG recommends that there is no responsibility for researchers to hunt or scan genetic and genomic data
or literature for changes in variant interpretation.
4. The ASHG recommends that any responsibility to recontact research participants is limited to the duration of
research funding. Recontact after the conclusion of funding may be desirable if sufficient resources exist.
5. The ASHG recommends that no responsibility to recontact participants exists when the IRB protocol associ-
ated with the study closes or identifiers are stripped, rendering further recontact infeasible.
6. The ASHG recommends that, when there is a strong recommendation for recontact, the recontact should
occur within 6 months of the reinterpretation.
7. The ASHG recommends that instances of recontact be documented.
8. The ASHG recommends that any responsibility for recontact is limited to a ‘‘good faith effort’’ to reach the
participant within the limits of existing constraints, including (but not limited to) financial and personnel re-
sources, the existence of accurate contact information for the participant, and willingness of the participant to
accept recontact.
9. The ASHG recommends that research projects develop a plan not only for initial return of results but also for
return (or not) of reinterpretations of those results. As part of that plan, research participants should be alerted
to the likelihood that interpretations of results might change over time and be given the opportunity to pro-
vide informed consent regarding the plan for return of results, including initial and reinterpreted results.
10. The ASHG recommends that, if the participant consented to any return of results at the time of original
research consent, then consent to recontact for the same type of results is implied and therefore appropriate
subject to the other recommendations in this policy statement.
11. The ASHG recommends that, ideally, the same individuals and communication methods that were used for
the initial return of results should be used for recontact.
12. The ASHG acknowledges that in the research context, participants might consent to initial return of a much
wider range of results. Thus, it is appropriate to return reinterpretations derived from reanalysis broader than
those addressed in this statement when that is consistent with study design and consent documents.a New Research Paradigm90’’) issued by the National Acad-
emy of Sciences, Engineering, and Medicine (NASEM)
included an entire chapter devoted to the issue of ‘‘reshap-
ing’’ the legal landscape to make it more conducive to the
return of individualized research results (see Chapter 6).
NASEM concluded that there was not yet legal consensus
on whether there is a right to access individualized
research results and highlighted some regulatory chal-
lenges for doing so. One such lack of consensus concerns
perceived regulatory conflicts between HIPAA’s right to ac-
cess and CLIA-certification requirements wherein some in-
dividuals, but notably not all legal experts, interpret that a
non-CLIA-certified laboratory’s provision of access to indi-
vidual research results in an effort to comply with the civil
right to access under HIPAA would necessitate that the
laboratory become CLIA certified. NASEM underscored
ethical and practical reasons for providing such access
to individual research participants and advocated for
harmonization and clarification of regulatory authorities
(including the Office for Civil Rights, the Centers for Medi-
care and Medicaid Services, and the U.S. Food and DrugThe AmeAdministration). NASEM noted among the many liability
concerns is the potential tort liability that might arise
from a ‘‘[f]ailure to update previously disclosed results
and to return the updated results.’’ Liability concerns,
NASEM notably concluded, could be alleviated through
the issuance of standards for reporting individual research
results. Among the areas in which clarity could emerge
(see NASEM Table 6-3) is whether there would be a more
specific articulation of what individual research data are
(or should be) considered as belonging to the HIPAA-desig-
nated record set (DRS) for mandatory disclosure.
These recommendations could also be informed and
updated in light of some much needed evidence. For
example, data concerning the benefits, risks, costs, proced-
ures, and outcomes of recontacting participants about re-
interpreted variants is limited, as is researchers’ experi-
ences with return of results and recontacting participants
about reinterpreted results. Reanalysing variant calls
and recontacting participants requires resources and fund-
ing, both of which are limited, or even non-existent,
in ongoing studies. Dedicated funding is required torican Journal of Human Genetics 104, 578–595, April 4, 2019 589
Figure 1. Recommended Pathway for Considering Recontacting Participants after Reinterpretation of Genetic and Genomic
Research Results
Reinterpretation refers to both reclassification of variants and reanalysis of original data (per the section ‘‘What Does It Mean to Rein-
terpret Results?’’). To be used in conjunction with recommendations listed in Box 1.
590 The American Journal of Human Genetics 104, 578–595, April 4, 2019
supplement researchers’ budgets to recontact participants,
through institutional mechanisms or built in as part of
future grant proposals. We urge funding agencies to
encourage and financially support researchers’ efforts to re-
contact participants in light of re-classified variants.
Enhancements in information technology (IT) will most
likely further reduce the opportunity costs of recontact and
open up new avenues of keeping patients and research par-
ticipants informed.Most electronicmedical record systems
and many clinical laboratories now offer portals through
which patients might see their data, interact with clinical,
laboratory, and support staff, and access educational mate-
rial. Databases can be interfaced and cross-referenced,
enabling more of a self-service model of education. Some
patients and participants are already being provided with
some or all of their raw genetic test result data, in addition
to the interpretation of that data. As our IT resources and
our databases continue to evolve, it is plausible that
much of the effort of recontact could become automated.
When a variant is reclassified, an automated notification
could be sent to all patients and subjects known to harbor
that variant, alerting them of the revised interpretation
and prompting them to log into the portal to view the
new information and associated education. This future
vision depends upon well-developed and interoperable
databases, including both the interpretations of the vari-
ants and the lists of who has each variant. Identifying
which databases to include (or exclude), as well as how
to manage conflicting data, will require effort. Some labo-
ratories have proposed databases or information technol-
ogy approaches to recontacting participants; some of these
technologies are used for tracking variant and patient data
and reclassifications and could send updated reports
directly to patients’ electronic medical records.18,91 Poten-
tially difficult questions about identity and privacy will
need to be answered. There are also significant concerns
about the ‘‘digital divide’’ and economic disparities;
increasing reliance on IT solutions has the potential to
discriminate against people who are unable to or choose
not to utilize such resources. There will always be situa-
tions that require more nuance and explanation than an
automated algorithm can achieve. But there is hope that
IT enhancements can significantly lower the costs and
barriers to recontacting research participants when it is
considered desirable to do so.Conclusion
Recontact after reinterpretation of genetic and genomic
research results is a complex issue in which clinical and
research laboratories, clinicians and researchers across spe-
cialties, and research participants all have potential roles to
play. Currently, research-related recontact typically hap-
pens on an ad hoc basis, which can lead to inequitable in-
formation provision and outcomes. Guidance is needed on
how recontact should be operationalized, and when andThe Amehow it should occur, especially in the research setting—a
setting where no guidance currently exists. This position
statement addresses this critical policy gap in order to pro-
vide necessary guidance to our research communities.
These recommendations are intended to provide a set of
principles; ultimately it is up to institutional review boards
and advisory boards as to how these principles are
operationalized.
These recommendations have been developed amidst an
evolving landscape of related policies andmight need to be
updated in light of the paucity of evidence on the burden
and outcomes of recontacting research participants. Future
research and changes in both IT and social values will most
likely impact our society’s approach to applying ethical
principles in conducting research and keeping researchpar-
ticipants as informed as possible about their genetic test re-
sults, even as our understanding of those test results evolves
over time. Development of the evidence base along with
ongoing stakeholder consultation is thus warranted if we
are to ensure the equitable and effective delivery of high-
quality research results to thosewhoparticipate in research.Acknowledgments
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